Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease

Celeste Roney, Padmakar Kulkarni, Veera Arora, Peter Antich, Frederick Bonte, Aimei Wu, N. N. Mallikarjuana, Sanjeev Manohar, Hsiang Fa Liang, Anandrao R. Kulkarni, Hsing Wen Sung, Malladi Sairam, Tejraj M. Aminabhavi

Research output: Contribution to journalArticlepeer-review

337 Scopus citations


Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (β-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

Original languageEnglish (US)
Pages (from-to)193-214
Number of pages22
JournalJournal of Controlled Release
Issue number2-3
StatePublished - Nov 28 2005


  • Alzheimer's disease
  • Blood-brain barrier
  • Central nervous system
  • Nanoparticles
  • Targeted drug delivery

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this